April 18th 2024
Compared with divided dosing, patients with once-daily dosing had shorter illness duration and better clinical outcomes.
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Recovery-Oriented Cognitive Therapy: Changing Lives With a Whole-Person Approach
January 23rd 2023Are you ready to understand how recovery-oriented cognitive therapy (CT-R) promotes wellness and empowerment for individuals experiencing serious mental health challenges? Check out this CME article.
Read More
Phase 3 Trial of Dexmedetomidine for Bipolar I or II, Schizophrenia Doses First Participants
November 30th 2022The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.
Read More
The Cross-Cultural Dimensions of Psychosis
November 11th 2022All medical students, psychiatry residents, fellows, faculty at academic medical institutions, and psychiatrists in independent practice must develop skills in cultural competence to avoid perpetuating disparities in health outcomes for BIPOC individuals with serious mental illnesses.
Read More